Tracking the relevant researches of CADD drug development against COVID-19
Tetrahydrofolic acid is a folic acid derivative that is produced from dihydrofolic acid after conversion by dihydrofolate reductase. It is converted into 5,10-methylenetetrahydrofolate by serine hydroxymethyltransferase. It is a soluble coenzyme in many reactions, especially in the metabolism of amino acids and nucleic acids. [DrugBank]
C-1-tetrahydrofolate synthase, cytoplasmic (Humans); Bifunctional methylenetetrahydrofolate dehydrogenase/cyclohydrolase, mitochondrial (Humans); Aminomethyltransferase, mitochondrial (Humans); Cytosolic 10-formyltetrahydrofolate dehydrogenase (Humans); Methionine synthase (Humans); Formimidoyltransferase-cyclodeaminase (Humans); Bifunctional purine biosynthesis protein PURH (Humans); Serine hydroxymethyltransferase, cytosolic (Humans); Serine hydroxymethyltransferase, mitochondrial (Humans); Methylenetetrahydrofolate reductase (Humans); Serine hydroxymethyltransferase (Humans); Methionyl-tRNA formyltransferase, mitochondrial (Humans) [DrugBank]
Tetrahydrofolate is the main active metabolite of dietary folate. It is vital as a coenzyme in reactions involving transfers of single carbon groups. Tetrahydrofolate has a role in nucleic and amino acid synthesis. As nucleic and amino acid synthesis is affected by a deficiency of tetrahydrofolate, actively dividing and growing cells tend to be the first affected. Tetrahydrofolate is used to treat topical sprue and megaloblastic and macrocytic anemias, hematologic complications resulting from a deficiency in folic acid. [DrugBank]
Tips: Click on the link to jump to the 'SwissTargetPrediction' webserver. Select the species of 'Homo sapiens', and then paste the SMILES of Tetrahydrofolic acid in the SMILES input box.
Tips: Click on the link to jump to the 'CB-Dock' webserver. Upload the structure file of target predicted by 'SwissTargetPrediction' and the 2D/3D structure file of Tetrahydrofolic acid to perform blind docking.